Cross-resistance within the protease inhibitor class.
Race
E
E
VIRALLIANCE, IMEA/INSERM, Hopital Bichat-Claude Bernard, Paris, France. race@bichat.inserm.fr
D019380:Anti-HIV Agents / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000502:physiology; D006801:Humans; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014779:Virus Replication
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D016333:HIV Protease